MicroRNA-16 Inhibits Migration and Invasion Via Regulation of the Wnt/β-catenin Signaling Pathway in Ovarian Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Mar 12

PMID 30854038

Citations 19

Authors

Nan Li

Liang Yang

Yanan Sun

Xiaohua Wu

Affiliations

Soon will be listed here.

Abstract

As small non-coding RNA molecules, microRNAs (miRs) function in the regulation of tumorigenesis. Proliferation in ovarian cancer is considered to be associated with miR-16; however, the role of miR-16 in the migration and invasion of ovarian cancer cells remains unclear. The results of the present study demonstrated that miR-16 expression is downregulated in the ovarian cancer SKOV3 and OVCAR3 cell lines compared with that in normal ovarian epithelial cells (OECs). miR-16 overexpression inhibited the proliferation, migration and invasion of SKOV3 and OVCAR3 cells, and decreased the expression of matrix metallopeptidase (MMP)2 and MMP9. Additionally, miR-16 upregulated the expression of cadherin 1, an intercellular adhesion molecule, and downregulated the expression of some mesenchymal markers, including snail family transcriptional repressor 2, snail family transcriptional repressor 1, Vimentin, twist family BHLH transcription factor 1 and cadherin 2 in SKOV3 and OVCAR3 cells. Furthermore, it was indicated that miR-16 overexpression in SKOV3 and OVCAR3 cells resulted in a significant increase in anti-glycogen synthase kinase 3 β expression and a decrease in the expression of Wnt family member 3A, β-catenin, MYC proto-oncogene, BHLH transcription factor and cyclin D1 compared with the NC group. The results of the present study indicated that miR-16 exerts a suppressive effect on cell migration and invasion in ovarian cancer , through inactivation of the Wnt/β-catenin signaling pathway. The data suggest that miR-16 may be a potential therapeutic agent for the treatment and prevention of ovarian cancer.

Citing Articles

The role of miR-16 and miR-34a family in the regulation of cancers: A review.

Sadeghi Z, Malekzadeh M, Sharifi M, Hashemibeni B Heliyon. 2025; 11(4):e42733.

PMID: 40061926 PMC: 11889592. DOI: 10.1016/j.heliyon.2025.e42733.

The Roles of MicroRNA-133 in Gynecological Tumors.

Zhou Y, Cheng Z Gynecol Minim Invasive Ther. 2022; 11(2):83-87.

PMID: 35746911 PMC: 9212183. DOI: 10.4103/GMIT.GMIT_79_20.

microRNA-16-5p suppresses cell proliferation and angiogenesis in colorectal cancer by negatively regulating forkhead box K1 to block the PI3K/Akt/mTOR pathway.

Huang X, Xu X, Ke H, Pan X, Ai J, Xie R Eur J Histochem. 2022; 66(2).

PMID: 35536149 PMC: 9134092. DOI: 10.4081/ejh.2022.3333.

Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.

Wilczynski J, Wilczynski M, Paradowska E Int J Mol Sci. 2022; 23(5).

PMID: 35269636 PMC: 8910575. DOI: 10.3390/ijms23052496.

Approaches Toward Targeting Matrix Metalloproteases for Prognosis and Therapies in Gynecological Cancer: MicroRNAs as a Molecular Driver.

Pandit A, Begum Y, Saha P, Srivastava A, Swarnakar S Front Oncol. 2022; 11:720622.

PMID: 35145899 PMC: 8821656. DOI: 10.3389/fonc.2021.720622.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli M, Degli Uberti E . miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005; 204(1):280-5. DOI: 10.1002/jcp.20282. View

Hanlon K, Rudin C, Harries L . Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One. 2009; 4(9):e7169. PMC: 2745703. DOI: 10.1371/journal.pone.0007169. View

Sonderegger S, Haslinger P, Sabri A, Leisser C, Otten J, Fiala C . Wingless (Wnt)-3A induces trophoblast migration and matrix metalloproteinase-2 secretion through canonical Wnt signaling and protein kinase B/AKT activation. Endocrinology. 2009; 151(1):211-20. PMC: 2974214. DOI: 10.1210/en.2009-0557. View

Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S . MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009; 69(23):9090-5. PMC: 2859686. DOI: 10.1158/0008-5472.CAN-09-2552. View

Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D . Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012; 10(12):1597-606. PMC: 3732195. DOI: 10.1158/1541-7786.MCR-12-0155-T. View

Li X, Ling N, Bai Y, Dong W, Hui G, Liu D . MiR-16-1 plays a role in reducing migration and invasion of glioma cells. Anat Rec (Hoboken). 2012; 296(3):427-32. DOI: 10.1002/ar.22626. View

Di Leva G, Croce C . The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Front Oncol. 2013; 3:153. PMC: 3682193. DOI: 10.3389/fonc.2013.00153. View

Arend R, Londono-Joshi A, Straughn Jr J, Buchsbaum D . The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013; 131(3):772-9. DOI: 10.1016/j.ygyno.2013.09.034. View

10.

Bodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W . Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res. 2014; 7:16. PMC: 3926861. DOI: 10.1186/1757-2215-7-16. View

11.

Ekinci T, Ozun Ozbay P, Yigit S, Yavuzcan A, Uysal S, Soylu F . The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer. Ginekol Pol. 2014; 85(2):121-30. DOI: 10.17772/gp/1702. View

12.

Wang Y, Kim S, Kim I . Regulation of Metastasis by microRNAs in Ovarian Cancer. Front Oncol. 2014; 4:143. PMC: 4050529. DOI: 10.3389/fonc.2014.00143. View

13.

Zhou X, Zhang H, Han X . Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives. Tumour Biol. 2014; 35(10):9523-30. DOI: 10.1007/s13277-014-2537-1. View

14.

Wei L, Liang H, Qin D, Jin H, Zhao Y, She M . MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. Tumour Biol. 2014; 35(12):12427-34. DOI: 10.1007/s13277-014-2560-2. View

15.

Wang Q, Li X, Zhu Y, Yang P . MicroRNA-16 suppresses epithelial-mesenchymal transition‑related gene expression in human glioma. Mol Med Rep. 2014; 10(6):3310-4. DOI: 10.3892/mmr.2014.2583. View

16.

Takai M, Terai Y, Kawaguchi H, Ashihara K, Fujiwara S, Tanaka T . The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer. J Ovarian Res. 2014; 7:76. PMC: 4127950. DOI: 10.1186/1757-2215-7-76. View

17.

Mohammadi Ghahhari N, Babashah S . Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015; 51(12):1638-49. DOI: 10.1016/j.ejca.2015.04.021. View

18.

Yeung T, Leung C, Yip K, Yeung C, Wong S, C Mok S . Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 2015; 309(7):C444-56. PMC: 4593771. DOI: 10.1152/ajpcell.00188.2015. View

19.

Amankwah E, Lin H, Tyrer J, Lawrenson K, Dennis J, Chornokur G . Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol. 2015; 39(8):689-97. PMC: 4721602. DOI: 10.1002/gepi.21921. View

20.

Wu W, Wang W, Yao W, Li G . Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells. Int J Mol Med. 2015; 36(6):1713-9. DOI: 10.3892/ijmm.2015.2379. View